Analysis of risk factors associated with common terminology criteria for adverse event in cancer chemotherapy patients
Keywords:
chemotherapy, adverse drug reaction, NCI-CTCAE, causalityAbstract
Background: Chemotherapeutic drugs are commonly associated with various harmful consequences which can remarkably reduce quality life of patient and lengthen hospital admission. The objective of this study was to evaluate the frequency and its associated factors affecting cancer chemotherapy-related side effects in cancer patients. Methods: Patient case report form was used to gather information on the patient's demographics and adverse drug reactions (ADRSs) to chemotherapy medications. ADRs were analyzed for toxicity grade using National Cancer Institute Common Terminology NCI-CTCAE version 4.0. Causality Assessment and Predictability of ADRs were analyzed using World Health Organization' (WHO) Causality assessment scale and Council for International Organization of Medical Sciences (CIOMS) method respectively. Utilizing the chi square test and descriptive statistics, the relationship between the grade of ADRs and the patient's characteristics was investigated. Results: A total of 120 patients were included in the study. Mean age of participant was 46.87 (SD-10.1). Majority (60%) participants were female. 81.7% of total patient received poly-chemotherapy in their treatment modality. Total 412 numbers of ADRs were noted. The most frequent adverse drug reactions were observed to be nausea and vomiting (17.7%), neutropenia and alopecia. On NCI-CTCAE grading maximum number of ADR was assessed as “Grade 2” ADR (33%).
Downloads
References
Albini A, Donatelli F, Noonan D, D’elios, MM, Prisco D. Bringing new players into the field: onco-pharmacovigilance in the era of cardiooncology. Intern Emerg Med. 2012;7(2):99–101.
Aranda S, Jefford M, Yates P, et al. Impact of a novel nurse-led pre chemotherapy education intervention on patient distress, symptom burden, and treatment-related information and support needs: results from a randomized, controlled trial. Ann Oncol. 2012;23(1): 222–231.
Baldo P, Fornasier G, Ciolfi L, Sartor I, Francescon S. Pharmacovigilance in oncology. International journal of clinical pharmacy. 2018 Aug;40(4):832-41.
Belachew S A et al. Pattern of chemotherapy-related adverse effects among adult cancer patients treated at Gondar University Referral Hospital, Ethiopia: a cross-sectional study Drug Healthc Patient Saf2016 Dec 8;8:83-90
Carmona-Bayonas A, Jimenez-Fonseca P, Castanon E, et al.Chronic opioid therapy in long-term cancer survivors. Clin Transl Oncol. 2017;19(2):236-250
Chabner BA. General principles of cancer chemotherapy. In: Brunton L, Dandan H, Knollman B, editors. Goodman and Gilman’s The Pharmacological Basis of Therapeutics. 13th ed. New York, NY: McGraw Hill Inc; 2018:1161–1167
Chan HK, Ismail S. Side effects of chemotherapy among cancer patients in a Malaysian general hospital: experiences, perceptions and informational needs from clinical pharmacists. Asian Pac J Cancer Prev. 2014;15(13):5305–5309.
Gandhi TK, Bartel SB, Shulman LN, et al. Medication safety in ambulatory chemotherapy setting. Cancer. 2005;104(11):2477–2483
GBD 2016 Cancer Collaborators. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2016: a systematic analysis for the Global Burden of Disease study. JAMA Oncol 2018; published online June 2. DOI:10.1001/ jamaoncol.2018.2706
Gita Thanarajasingam, MD et al., Beyond Maximum Grade: Modernizing Adverse Event Assessment and Reporting in Haematologic Malignancies. Lancet Haematol. 2018 November; 5(11): e563–e598.
Gnjidic D, Hilmer SN, Blyth FM, et al. Polypharmacy cutoff and outcomes: five or more medicines were used to identify community-dwelling older men at risk of different adverse outcomes
https://cioms.ch › wp-content › uploads › 2017/01, REPORTING ADVERSE DRUG REACTIONS
India state level disease burden initiative cancer collaborators. Lancet Oncol. 2018 Oct;19(10): 1289-1306
Lau PM, Stewart K, Dooley M. The ten most common adverse drug reactions in oncology (ADRs) in oncology patients : Do they matter to you? Support Care Cancer. 2004;12:626-33.
Lavan, O’Mahony, Buckley et al. Adverse Drug Reactions in an Oncological Population: Prevalence, Predictability, and Preventability The Oncologist 2019;24:e968–e977
Malcolm R Alison. Cancer. London, UK: Imperial College, School of Medicine, encyclopedia of life science: 2001:27–43.
Mangoni AA, Jackson SHD. Age-related changes in pharmacokineticsand pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol. 2004;57(1):6-14.
Maryam B. Lustberg, Management of Neutropenia in Cancer Patients. Clin Adv Hematol Oncol. 2012 December ; 10(12): 825–826.
Meyboom RH, Egberts AC, Gribnau FW, et al.: Pharmacovigilance in perspective. Drug Saf. 1999; 21(6): 429–447.
Mohile SG, Magnuson A. Comprehensive geriatric assessmentin oncology. Interdiscip Top Gerontol. 2013;38:85-103
Poddar S, Sultana R, Akbor MM, Azad MA, Hasnat A. Pattern of adverse drug reactions due to cancer chemotherapy in tertiary care teaching hospital in Bangladesh. Dhaka Univ J Pharm Sci. 2009;8:11–16.
Prashant Mathur et al. Cancer Statistics, 2020: Report From National Cancer Registry Programme, India JCO Glob Oncol. 2020 Jul;6:1063-1075.
Puts MT, Costa-Lima B, Monette J, et al. Medication problems in older, newly diagnosed neoplasm patients in Canada: How common are they? A prospective pilot study. Drugs Aging. 2009;26(6):519-536.
Rock EM and Parker LA (2016) Cannabinoids As Potential Treatment for Chemotherapy-Induced Nausea and Vomiting. Front. Pharmacol. 7:221.
Rossi A. et al, Chemotherapy-induced alopecia management: clinical experience and practical advice. J Cosmet Dermatol. 2017 December ; 16(4): 537–541
Sharma PK, Misra AK, Gupta A, Singh S, Dhamija P, Pareek P. A retrospective analysis of reporting of adverse drug reactions to oncology drugs: An experience from a national center of clinical excellence. Indian Journal of Pharmacology. 2018 Sep;50(5):273.
The burden of cancer and their variation across the states of India: the global burden of disease study 1990-2016.
Tian Qi Wang et al., Routine Surveillance of Chemotherapy Toxicitiesin Cancer Patients Using the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE), Oncol Ther (2018) 6:189–201.
U.S Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE). U.S Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Version4.0.2010. https://evs.nci.nih.gov/ftp1/CTCAE/Archive/CTCAE_4.02_2009-09-15_QuickReference_8.5x11.pdf
World Health Organization. Uppsala Monitoring Center. Causality assessment of suspected adverse reactions 2014. Available from: http:// who.umc.org/graphics/24734.pdf
Xincai Zhao et al., Impacts of Pharmacists-Managed Oncology Outpatient Clinic on Resolving Drug-Related Problems in Ambulatory Neoplasm Patients: A Prospective Study in China. Inquiry 2021 Jan-Dec; 58: 00469580211009662
Yong Wang, Virginia Probin, and Daohong Zhou, Cancer therapy-induced residual bone marrow injury-Mechanisms of induction and implication for therapyCurr Cancer Ther Rev. 2006 August 1; 2(3): 271–279
Published
How to Cite
Issue
Section
Copyright (c) 2022 International journal of health sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Articles published in the International Journal of Health Sciences (IJHS) are available under Creative Commons Attribution Non-Commercial No Derivatives Licence (CC BY-NC-ND 4.0). Authors retain copyright in their work and grant IJHS right of first publication under CC BY-NC-ND 4.0. Users have the right to read, download, copy, distribute, print, search, or link to the full texts of articles in this journal, and to use them for any other lawful purpose.
Articles published in IJHS can be copied, communicated and shared in their published form for non-commercial purposes provided full attribution is given to the author and the journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
This copyright notice applies to articles published in IJHS volumes 4 onwards. Please read about the copyright notices for previous volumes under Journal History.
